PAR HEALTH: ELEVATING THE ESSENTIALS
LIVE

Serial Number

79437203

Owner

PH Health Limited

Attorney

Camille M. Miller

Filing Date

Oct 7, 2025

Add to watchlist:

No watchlists yet
View on USPTO

PAR HEALTH: ELEVATING THE ESSENTIALS Trademark

Serial Number: 79437203 • Registration: 8290339

PAR HEALTH: ELEVATING THE ESSENTIALS is a trademark filed by PH Health Limited on October 7, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

PH Health Limited

First Floor, Minerva House,

Entity Type: 77

Trademark Details

Filing Date

October 7, 2025

Registration Date

June 9, 2026

Published for Opposition

April 21, 2026

Goods & Services

Custom manufacture of pharmaceutical products to the order and specification of others; providing technical information in the field of pharmaceutical manufacturing.

Charitable services, namely patient assistance programs that provide pharmaceuticals to help patients with low income get pharmaceuticals at little or no cost to the patient.

Outsourcing services in the nature of arranging procurement of goods for others in the field of pharmaceuticals; business administration of patient reimbursement programs for pharmaceuticals; business administration of patient assistance programs that provide pharmaceuticals to help patients with insufficient resources get treatment at little or no cost to the patient.

Pharmaceutical products for the treatment of pain management, infectious diseases, central nervous system disorders, namely epilepsy, anxiety, and depression, hypertension, cholesterol management, heart disease, acid reflex, ulcers and irritable bowel syndrome, diabetes, thyroid disorders, side effects of cancer treatments, bone diseases, allergic reactions, shock, malignant diseases, and kidney disorders; pharmaceutical preparations for the treatment of pain management, infectious diseases, central nervous system disorders, namely epilepsy, anxiety, and depression, hypertension, cholesterol management, heart disease, acid reflex, ulcers and irritable bowel syndrome, diabetes, thyroid disorders, side effects of cancer treatments, bone diseases, allergic reactions, shock, malignant diseases, and kidney disorders; ready-to-administer injectable pharmaceutical preparations for the treatment of allergic reactions, hypotension, shock, malignant diseases, and kidney disorders, and to provide and reverse muscle relaxation to be used in patient care facilities, namely, hospitals, acute care facilities, and long term care facilities; radio frequency identification tagged pharmaceutical products, namely, sympathomimetic agents, diagnostic agents, anticoagulants, thrombin inhibitors, anesthetics, analgesics, endocrine metabolics, antibacterial agents, antibiotics, skeletal muscle relaxants, injectable estrogens, diuretic agents, psychiatrics, antivirals, thyroid agents, corticosteroids, antifungals, immunosuppressive agents, parasympathomimetic agents, vasoconstrictors, oxytocic agents, antiemetics, vasopressin antagonists, vasodilators, vasopressors, anti-epileptics, anticonvulsants, cholinesterase inhibitors, and antimuscarinic agents.

Development of pharmaceutical preparations and medicines; pharmaceutical drug development services; pharmaceutical research and development; pharmaceutical research services.

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 9, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 9, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 21, 2026 NPUB
PUBLISHED FOR OPPOSITION
Apr 21, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 15, 2026 NONP
REFUSAL PROCESSED BY IB
Apr 9, 2026 RFNT
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 26, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 25, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 25, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 25, 2026 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 21, 2026 RFCS
REFUSAL PROCESSED BY MPU
Mar 21, 2026 RFRR
NEW REPRESENTATIVE AT IB RECEIVED
Mar 5, 2026 NREP
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 18, 2026 RFCR
NON-FINAL ACTION WRITTEN
Feb 17, 2026 CNRT
ASSIGNED TO EXAMINER
Feb 17, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 21, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 21, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 20, 2025 REPR